BIOPORTO A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 DKK | -2.49% |
|
-5.26% | -13.88% |
| May. 08 | BioPorto A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 08 | Bioporto A/S Provides Earnings Guidance for 2024 | CI |
Presentation Operator MessageOperator (Operator)Good afternoon, everybody, and good morning to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Companyâs portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Calendar
2024-08-14
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.846
DKK
Average target price
5
DKK
Spread / Average Target
+170.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.88% | 102M | |
| -4.67% | 12.33B | |
| -5.19% | 8.14B | |
| +31.05% | 5.62B | |
| -8.09% | 4.24B | |
| -54.52% | 3.06B | |
| +13.49% | 2.76B | |
| -1.34% | 2.41B | |
| +32.39% | 2.23B | |
| -3.55% | 1.87B |
- Stock Market
- Equities
- BIOPOR Stock
- News BioPorto A/S
- Transcript : BioPorto A/S, Q1 2023 Earnings Call, May 10, 2023
